Medivir (OM:MVIR) - Stock Price, News & Analysis

MVIR Stock Overview

Medivir AB (publ), empresa farmacéutica, centra su actividad en el desarrollo y la comercialización de tratamientos contra el cáncer en la región nórdica, el resto de Europa y a escala internacional.

About the company

MVIR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Se prevé un crecimiento anual de los ingresos de 59.63%

Risk Analysis

Los accionistas se han diluido sustancialmente en el último año

Tiene unos ingresos inferiores a 1 millón de dólares (SEK8M)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

No tiene una capitalización bursátil significativa (SEK363M)

+ 1 more risk

Medivir AB (publ) Competitors

Nanologica

OM:NICA

kr282.7m

Oncopeptides

OM:ONCO

kr511.6m

ExpreS2ion Biotech Holding

OM:EXPRS2

kr113.1m

Biovica International

OM:BIOVIC B

kr199.2m

Price History & Performance

Summary of all time highs, changes and price drops for Medivir
Historical stock prices
Current Share Price	kr2.67
52 Week High	kr8.58
52 Week Low	kr2.50
Beta	-0.19
1 Month Change	-2.23%
3 Month Change	-10.10%
1 Year Change	-65.68%
3 Year Change	-68.95%
5 Year Change	-86.81%
Change since IPO	-97.99%

Recent updates

Shareholder Returns

	MVIR	SE Biotechs	SE Market
7D	-2.8%	-2.3%	-0.8%
1Y	-65.7%	-1.4%	13.0%

Rentabilidad frente al sector: MVIR obtuvo unos resultados inferiores a los del sector Swedish Biotechs , que el año pasado arrojó un rendimiento del -2.4%.

Rentabilidad vs. Mercado: MVIR obtuvo unos resultados inferiores a los del mercado Swedish, que fue del 4.8% el año pasado.

Price Volatility

Is MVIR's price volatile compared to industry and market?
MVIR volatility
MVIR Average Weekly Movement	9.0%
Biotechs Industry Average Movement	9.1%
Market Average Movement	6.1%
10% most volatile stocks in SE Market	13.3%
10% least volatile stocks in SE Market	3.5%

Precio estable de las acciones: MVIRha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: MVIR(14%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de Swedish.

About the Company

Founded	Employees	CEO	Website
1987	10	Jens Lindberg	https://www.medivir.com

Medivir AB (publ), empresa farmacéutica, se centra en el desarrollo y la comercialización de tratamientos contra el cáncer en la región nórdica, el resto de Europa y a escala internacional. La empresa comercializa Xerclear para el tratamiento del herpes labial con el nombre de Zoviduo. También está desarrollando Remetinostat para tratar el linfoma cutáneo de células T MF y el carcinoma basocelular, así como el carcinoma de células escamosas.

Medivir AB (publ) Fundamentals Summary

How do Medivir's earnings and revenue compare to its market cap?
MVIR fundamental statistics
Market cap	kr299.15m
Earnings (TTM)	-kr89.30m
Revenue (TTM)	kr7.60m

39.4x

P/S Ratio

-3.3x

P/E Ratio

Is MVIR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MVIR income statement (TTM)
Revenue	kr7.60m
Cost of Revenue	kr68.90m
Gross Profit	-kr61.30m
Other Expenses	kr28.00m
Earnings	-kr89.30m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)	-0.80
Gross Margin	-806.58%
Net Profit Margin	-1,175.00%
Debt/Equity Ratio	0%

How did MVIR perform over the long term?

See historical performance and comparison

MVIR Stock Overview

Rewards

Risk Analysis

Medivir AB (publ) Competitors

OM:NICA

kr282.7m

OM:ONCO

kr511.6m

OM:EXPRS2

kr113.1m

OM:BIOVIC B

kr199.2m

Price History & Performance

Recent News & Updates

Consensus revenue estimates fall by 90%

Price target decreased by 8.2% to kr22.49

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

New major risk - Shareholder dilution

Recent updates

Consensus revenue estimates fall by 90%

Price target decreased by 8.2% to kr22.49

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

New major risk - Shareholder dilution

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Price target decreased by 16% to kr23.39

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 78%

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

High number of new and inexperienced directors

Consensus revenue estimates increase by 47%, EPS downgraded

Independent Chairman of the Board recently bought kr374k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Medivir AB Announces Patent Application for Fostrox Approval in China

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Chief Executive Officer recently bought kr209k worth of stock

Price target increased by 14% to kr28.08

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 16%, revenue upgraded

Price target increased by 13% to kr27.96

Forecast to breakeven in 2024

Less than half of directors are independent

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

New 90-day low: kr8.00

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant